Ann Arbor, MICHIGAN4 Active Studies

Hemophilia Clinical Trials in Ann Arbor, MICHIGAN

Find 4 actively recruiting hemophilia clinical trials in Ann Arbor, MICHIGAN. Connect with local research sites and explore new treatment options.

4
Active Trials
3
Sponsors
207
Enrolling

Recruiting Hemophilia Studies in Ann Arbor

RecruitingAnn Arbor, MICHIGANNCT06379789

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an ex...

130 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingAnn Arbor, MICHIGANNCT06003387

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreat...

35 participants
CSL Behring
View Study Details
RecruitingAnn Arbor, MICHIGANNCT06611436

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 ...

24 participants
Be Biopharma
View Study Details
RecruitingAnn Arbor, MICHIGANNCT07080905

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participant...

18 participants
CSL Behring
View Study Details

About Hemophilia Clinical Trials in Ann Arbor

Hemophilia is a rare genetic bleeding disorder in which blood does not clot properly due to deficiency of clotting factors. Hemophilia A (factor VIII) and hemophilia B (factor IX) are the most common types. Treatment includes factor replacement therapy and newer approaches like gene therapy.

There are currently 4 hemophilia clinical trials recruiting participants in Ann Arbor, MICHIGAN. These studies are seeking a combined 207 participants. Research is being sponsored by Regeneron Pharmaceuticals, CSL Behring, Be Biopharma. Clinical trial participation is free and participants receive study-related medical care at no cost.

Hemophilia Clinical Trials in Ann Arbor — FAQ

Are there hemophilia clinical trials in Ann Arbor?

Yes, there are 4 hemophilia clinical trials currently recruiting in Ann Arbor, MICHIGAN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Ann Arbor?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.

Are clinical trials in Ann Arbor free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.

What hemophilia treatments are being tested?

The 4 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for hemophilia.

Data updated March 2, 2026 from ClinicalTrials.gov